Cite
FRI-473-Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study
MLA
Mario Cristobal Romero, et al. “FRI-473-Safety and Effectiveness of Regorafenib in Recurrent HCC after Liver Transplantation and Progression on Sorafenib: A Real-Life Multicentre Study.” Journal of Hepatology, vol. 70, Apr. 2019, pp. e606–07. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6dfc6b83afb8290106ef6906a6b73bf5&authtype=sso&custid=ns315887.
APA
Mario Cristobal Romero, Matthias Pinter, Maria Margarita Anders, Wörns Marcus, Vincenzo Mazzaferro, Pietro Lampertico, Aballay Soteras Gabriel Alejandro, Maria Varela, Federico Piñero, Maria Reig, Sherrie Bhoori, Federica Invernizzi, Massimo De Giorgio, Carolin Czauderna, Maria Jose Blanco Rodríguez, Gonzalo Crespo, Gerda Elisabeth Villadsen, Massimo Lavarone, Arndt Weinmann, … Giuliana Amaddeo. (2019). FRI-473-Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study. Journal of Hepatology, 70, e606–e607.
Chicago
Mario Cristobal Romero, Matthias Pinter, Maria Margarita Anders, Wörns Marcus, Vincenzo Mazzaferro, Pietro Lampertico, Aballay Soteras Gabriel Alejandro, et al. 2019. “FRI-473-Safety and Effectiveness of Regorafenib in Recurrent HCC after Liver Transplantation and Progression on Sorafenib: A Real-Life Multicentre Study.” Journal of Hepatology 70 (April): e606–7. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6dfc6b83afb8290106ef6906a6b73bf5&authtype=sso&custid=ns315887.